BMS to Invest $400 Million in Expansion of Dublin Site
Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin, Ireland, significantly expanding manufacturing and laboratory capacity at the site.
BMS said that this will be its first European SDP facility for biologics manufacturing and is currently in the design phase. Construction is expected to start in March 2024, with completion scheduled for 2026.
As part of this investment, BMS expects to create 350 additional jobs in Ireland, bringing the total number of employees on the campus to more than 1,000.
Padraig Keane, vice president of Cruiserath Biologics at BMS, said: “This investment will expand our capacity for aseptic drug products, reinforce stable production for global supply, and accelerate the development and commercialization of innovative biologic therapies alongside other pipeline medicines. This year we celebrate 60 years of BMS in Ireland, across our three sites in Ireland we continue to play a critical role in the global production, development, and supply network.”
Karin Shanahan, BMS’ executive vice president, Global Product Development and Supply, added: “The Cruiserath Biologics site will continue to play a crucial role in our company’s success moving forward. Coupled with the breadth of knowledge and expertise of our employees, this sterile drug product site, co-partnered alongside our biologics facility, will allow us to further enhance our operations as we strive to get more medicines to more patients faster.”
